Hypersensitivity Pneumonitis Market Research Report – Global Forecast till 2030

Hypersensitivity Pneumonitis Market Research Report, By Type (Acute, Subacute, Chronic), By Therapy (Diagnosis (Chest Lung Function Tests, X-Ray, Lung Biopsy) Treatment (Pharmacological (Corticosteroid))), End User (Hospital) - Global Forecast till 2027

ID: MRFR/Pharma/3228-HCR | January 2023 | Region: Global | 110 Pages         

Hypersensitivity Pneumonitis Market Speak to Analyst Request a Free Sample

Hypersensitivity Pneumonitis Market Scenario:The hypersensitivity pneumonitis market is expected to reach USD 1,503.50 Million by 2030 at 4.10% CAGR during the forecast period 2022-2030.Hypersensitivity pneumonitis is a complex syndrome caused due to exposure to a variety of organic particles. Hypersensitivity pneumonitis is divided into three types, acute hypersensitivity pneumonitis, subacute hypersensitivity pneumonitis, and chronic hypersensitivity pneumonitis which is based on the based on the duration of the illness. According to the American Academy of Allergy, Asthma & Immunology (2013), 10%-30% of the global population suffers from allergic rhinitis. Increasing prevalence of patients suffering from hypersensitivity pneumonitis, and increasing pollution have boosted the growth of the market. Additionally, According to the American Academy of Allergy, Asthma & Immunology, in 2013, globally, sensitization rates to one or more common allergens among school children is approximately 40%-50% and in 2012, 10.6% children were diagnosed with respiratory allergies. Moreover, increasing prevalence of respiratory diseases, increasing healthcare expenditure, and strong government support for research & development have also contributed to the growth of the market. Rising geriatric population also supports the growth of the market. However, lack of long term treatment and awareness about the diseases may lead to slow the growth of Hypersensitivity Pneumonitis Market.


Intended Audience



  • Pharmaceutical companies

  • Biotechnological institutes

  • Medical Devices Companies

  • Government and Private Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Medical Research Laboratories 


Figure 1:-  Hypersensitivity pneumonitis market share, by region Hypersensitivity Pneumonitis Market


Sources: WHO, annual reports, press release, white paper, and company presentation 


Segmentation


The hypersensitivity pneumonitis market is segmented on the basis of types, therapy, and end users.


On the basis of types, the market is segmented into acute hypersensitivity pneumonitis, subacute hypersensitivity pneumonitis, and chronic hypersensitivity pneumonitis.


On the basis of therapy, the market is segmented into diagnosis, and treatment. Diagnosis is further segmented into chest lung function tests, X-ray, lung biopsy, and others. Treatment is further classified into pharmacological and non-pharmacological. Pharmacological is further segmented into corticosteroid therapy, immunosuppressive therapy and others.


On the basis of end users, the Hypersensitivity Pneumonitis Market is segmented into hospital, clinics, and others. 


Regional Analysis


America commands the largest share in the hypersensitivity pneumonitis market owing to a relatively larger patient population suffering from respiratory allergy and huge geriatric population. According to the Asthma and Allergy Foundation of America, in 2015, 8.2% of adults and 8.4% of children were diagnosed with hay fever. The report also states that, annual cost of allergies exceeds USD 18 billion and food allergies cost about USD 25 billion per year. Changing lifestyle, high healthcare spending and increasing geriatric population have boosted the growth of the market in America. Additionally, increasing awareness among the people regarding different diagnostic procedures has also supported the growth of the market.


Europe is the second largest market for hypersensitivity pneumonitis, which is followed by Asia Pacific. Availability of funds for research, changing environment conditions and government support for research & development will drive the market.


Asia Pacific is expecting fastest growth for the market due to the presence of a huge patient population, presence of huge opportunity in the market, and huge geriatric population. India and China are the major contributors for the market. According to the WHO in 2013, approximately 20-30% of Indian population suffers from at least one allergic disease and 8.7% of the total china’s population suffers from allergic rhinitis. Increasing prevalence of diseases have boosted the growth of the Asia Pacific market.


On the other hand, the Middle East & Africa holds the least share in the hypersensitivity pneumonitis market due limited development in the healthcare sector and poor economy in Africa region. Majority of the market of this region is held by the Middle East due to huge healthcare spending.


Research Methodology Hypersensitivity Pneumonitis Market-


Sources: WHO, annual reports, press release, white paper, and company presentation


Key players for hypersensitivity pneumonitis market


The key players for the hypersensitivity pneumonitis market: Novartis (Switzerland), Abbott (U.S.), AstraZeneca (U.K), Abbott (US) Eli Lilly (U.S.), Bayer Cropscience Ltd. (U.S.).,  Sunpharma (India), Merck & Co. (U.S.), Pfizer (U.



Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Hypersensitivity pneumonitis market is projected to grow at an 4.10% CAGR between 2022- 2030.

The Americas is expected to dominate the hypersensitivity pneumonitis market.

Major end users of hypersensitivity pneumonitis market include clinics, hospitals, and others.

Increasing awareness and high healthcare spending are the key factors driving the hypersensitivity pneumonitis market growth.

Key players profiled in the hypersensitivity pneumonitis market include Novo Nordisk (Denmark), Sanofi (France), F. Hoffman La Roche AG (Germany), Svizera Healthcare (India), Pfizer (U.S.), Merck & Co. (U.S.), Sunpharma (India), Bayer Cropscience Ltd. (U.S.)., Eli Lilly (U.S.), Abbott (US), AstraZeneca (U.K), Abbott (U.S.), and Novartis (Switzerland).